Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma-Reference-Cited by-同舟云学术

Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma

Published:2017-09-08 Issue:9 Volume:12 Page:e0184423
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Amzal Billy,Fu Shuai,Meng Jie,Lister Johanna^ORCID,Karcher Helene

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;J Ferlay;Int J Cancer,2015

2. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;J Ferlay;Eur J Cancer,2013

3. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review;K Gupta;Cancer Treat Rev,2008

4. International variations and trends in renal cell carcinoma incidence and mortality;A Znaor;Eur Urol,2015

5. Renal-cell carcinoma;HT Cohen;N Engl J Med,2005

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Metastatic Renal Cell Carcinoma Following First-Line Immune Checkpoint Therapy Failure: A Systematic Review;Cancers;2024-07-20

2. Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”;Human Vaccines & Immunotherapeutics;2024-05-17

3. Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-04-17

4. Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update;Journal of Cancer Research and Clinical Oncology;2024-04-09

5. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024;Journal of the National Comprehensive Cancer Network;2024-02